Hemab Therapeutics (COAG) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.42 billion vs $1.12 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | IMTX |
|---|---|---|
| Share price | $30.45 | $7.39 |
| Market cap | $1.42B | $1.12B |
| 1-day change | +6.10% | -0.81% |
| YTD return | — | -29.05% |
| 1-year return | — | -20.83% |
| 5-year return | — | -46.21% |
| EPS (TTM) | $-4.33 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $12.41 |
| 52-week low | $23.00 | $7.02 |
| Distance from 52-week high | -45.06% | -40.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +100.99% | +138.57% |
| Average volume | 453.97K | 595.07K |
| Shares outstanding | 46.71M | 152.23M |
| Employees | 59 | 704 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
COAG vs IMTX FAQ
Which is bigger, Hemab Therapeutics or Immatics N.V.?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.42B compared with $1.12B for Immatics N.V. (IMTX).
Are Hemab Therapeutics and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.